Related Experiment Video

Updated: Aug 15, 2025

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.4K

The Current State of Knowledge About Evolution of Multiple Myeloma to Plasma Cell Leukemia

Artur Jurczyszyn1, Magdalena Olszewska-Szopa2, David H Vesole3

  • 1Hematology Department, Jagiellonian University Medical College, Cracow, Poland.

Clinical Lymphoma, Myeloma & Leukemia
|January 2, 2023
PubMed

Insights

Secondary plasma cell leukemia (sPCL) is an aggressive multiple myeloma (MM) complication. Understanding sPCL

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Multiple myeloma (MM) survival is increasing, leading to more secondary plasma cell leukemia (sPCL) cases.
  • Primary plasma cell leukemia (pPCL) is a rare MM presentation.
  • Secondary plasma cell leukemia (sPCL) is a transformation from MM.

Observation:

  • Secondary plasma cell leukemia (sPCL) is aggressive with a poor prognosis.
  • Data on sPCL presentation, treatment, and outcomes is limited.
  • The molecular basis of sPCL is poorly understood.

Findings:

  • This review synthesizes current knowledge on sPCL.
  • It covers diagnostics, molecular biology, clinical characteristics, and prognosis.
  • Emerging therapeutic strategies for sPCL are discussed.

Implications:

  • Addressing the unmet medical need in sPCL is crucial.
  • Improved understanding can guide treatment strategies.
  • Further research into sPCL molecular biology is warranted.
Keywords:
DiagnosisPlasma cell dyscrasiaPrognosisSecondary plasma cell leukemiaTherapy

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.3K

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K